Crinetics Pharmaceuticals Capital Expenditures (CapEx) Growth & History (CRNX)
Crinetics Pharmaceuticals's capital expenditures (capex) was $5.8M for fiscal 2025.
View full Crinetics Pharmaceuticals company overviewCrinetics Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.8M | $1.9M | +49.90% |
| 2024 | 2024-12-31 | $3.8M | −$844,000 | −18.00% |
| 2023 | 2023-12-31 | $4.7M | $3.0M | +183.09% |
| 2022 | 2022-12-31 | $1.7M | $1.2M | +279.82% |
| 2021 | 2021-12-31 | $436,000 | $250,000 | +134.41% |
| 2020 | 2020-12-31 | $186,000 | −$306,000 | −62.20% |
| 2019 | 2019-12-31 | $492,000 | −$567,000 | −53.54% |
| 2018 | 2018-12-31 | $1.1M | $755,000 | +248.36% |
| 2017 | 2017-12-31 | $304,000 | $114,000 | +60.00% |
| 2016 | 2016-12-31 | $190,000 | — | — |
Crinetics Pharmaceuticals quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $521,000 | −$2.7M | −83.73% |
| Q1 2026 | 2026-03-31 | $820,000 | −$419,000 | −33.82% |
| Q4 2025 | 2025-12-31 | $458,000 | −$571,000 | −55.49% |
| Q3 2025 | 2025-09-30 | $863,000 | $335,000 | +63.45% |
| Q2 2025 | 2025-06-30 | $3.2M | $2.2M | +235.29% |
| Q1 2025 | 2025-03-31 | $1.2M | −$93,000 | −6.98% |
| Q4 2024 | 2024-12-31 | $1.0M | $94,000 | +10.05% |
| Q3 2024 | 2024-09-30 | $528,000 | −$3.0M | −84.91% |
| Q2 2024 | 2024-06-30 | $955,000 | $718,000 | +302.95% |
| Q1 2024 | 2024-03-31 | $1.3M | $1.3M | +8225.00% |
| Q4 2023 | 2023-12-31 | $935,000 | $661,000 | +241.24% |
| Q3 2023 | 2023-09-30 | $3.5M | $2.8M | +413.20% |
| Q2 2023 | 2023-06-30 | $237,000 | −$376,000 | −61.34% |
| Q1 2023 | 2023-03-31 | $16,000 | −$71,000 | −81.61% |
| Q4 2022 | 2022-12-31 | $274,000 | $256,000 | +1422.22% |
| Q3 2022 | 2022-09-30 | $682,000 | $542,000 | +387.14% |
| Q2 2022 | 2022-06-30 | $613,000 | $451,000 | +278.40% |
| Q1 2022 | 2022-03-31 | $87,000 | −$29,000 | −25.00% |
| Q4 2021 | 2021-12-31 | $18,000 | $1,000 | +5.88% |
| Q3 2021 | 2021-09-30 | $140,000 | $43,000 | +44.33% |
| Q2 2021 | 2021-06-30 | $162,000 | $150,000 | +1250.00% |
| Q1 2021 | 2021-03-31 | $116,000 | $56,000 | +93.33% |
| Q4 2020 | 2020-12-31 | $17,000 | −$11,000 | −39.29% |
| Q3 2020 | 2020-09-30 | $97,000 | $97,000 | — |
| Q2 2020 | 2020-06-30 | $12,000 | −$44,000 | −78.57% |
| Q1 2020 | 2020-03-31 | $60,000 | −$348,000 | −85.29% |
| Q4 2019 | 2019-12-31 | $28,000 | −$254,000 | −90.07% |
| Q3 2019 | 2019-09-30 | $0 | −$251,000 | — |
| Q2 2019 | 2019-06-30 | $56,000 | −$413,000 | −88.06% |
| Q1 2019 | 2019-03-31 | $408,000 | $351,000 | +615.79% |
| Q4 2018 | 2018-12-31 | $282,000 | — | — |
| Q3 2018 | 2018-09-30 | $251,000 | $233,000 | +1294.44% |
| Q2 2018 | 2018-06-30 | $469,000 | — | — |
| Q1 2018 | 2018-03-31 | $57,000 | — | — |
| Q3 2017 | 2017-09-30 | $18,000 | — | — |
Crinetics Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Crinetics Pharmaceuticals's capital expenditures (capex) increased from $186,000 to $5.8M, a change of $5.6M. The latest reported quarter, Q2 2026, shows $521,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Crinetics Pharmaceuticals source filings ↗